Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

BackgroundOlaparib has been proven for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy and safety of the combination of olaparib and abiraterone in patients with mCRPC.MethodsThe literature in PubMed, Embase,...

Full description

Bibliographic Details
Main Authors:	Zhanyang Luo, Bukun Zhu, Hong Xu, Lixin Chen, Xiaoyun Song, Yu Wang, Rui Wang, Jinzhou Zheng, Yunhua Qiu, Jianfeng Yang, Youyang Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Oncology
Subjects:	olaparib abiraterone metastatic castration-resistant prostate cancer (mCRPC) efficacy safety meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1265276/full

Similar Items

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
by: Dan Su, et al.
Published: (2021-01-01)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: ZhenHeng Wei, et al.
Published: (2021-08-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
by: Evgeniya Sharova, et al.
Published: (2021-03-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
by: Huub H. van Rossum, et al.
Published: (2023-02-01)

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
by: Chang Liu, et al.
Published: (2020-05-01)

Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
by: Zhengquan Xu, et al.
Published: (2021-03-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Hualin Song, et al.
Published: (2020-03-01)

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
by: Alexandre Mendonça Macedo, et al.
Published: (2023-02-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
by: Yozo Mitsui, et al.
Published: (2023-06-01)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
by: Liancheng Fan, et al.
Published: (2018-12-01)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
by: Hao Xiang Chen, et al.
Published: (2023-07-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
by: Yu-Chao Ni, et al.
Published: (2022-01-01)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
by: Matsumoto T, et al.
Published: (2022-08-01)

Current management of metastatic castration-sensitive prostate cancer
by: Adam Kessel, et al.
Published: (2021-01-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
by: Marcus Moses, MS, et al.
Published: (2020-01-01)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
by: Min Liu, et al.
Published: (2023-05-01)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
by: Takashi Kawahara, et al.
Published: (2023-03-01)

Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer
by: Zhi‐Bin Ke, et al.
Published: (2023-04-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
by: Wei Ning, et al.
Published: (2023-09-01)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
by: Javier Puente, et al.
Published: (2019-08-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
by: Oliver E. Yausep, et al.
Published: (2019-08-01)

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
by: Majid Assadi, et al.
Published: (2022-12-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
by: Jian Pan, et al.
Published: (2022-12-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
by: Laura Dupuy, et al.
Published: (2013-06-01)

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
by: Henrik Suttmann, et al.
Published: (2020-09-01)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
by: Bram De Laere, et al.
Published: (2021-03-01)